Hostname: page-component-78c5997874-lj6df Total loading time: 0 Render date: 2024-11-10T09:06:49.905Z Has data issue: false hasContentIssue false
  • English
  • Français

First and second generation antipsychotics: translating the results from pragmatic trials into clinical practice

Published online by Cambridge University Press:  07 February 2013

S. R. Marder
S. R. Marder*
Affiliation:
West Los Angeles VA Healthcare Center, Semel Institute at UCLA, Los Angeles, USA
*
Address for correspondence: Professor S.R. Marder, West Los Angeles VA Healthcare Center, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA. (Email: SMarder@mednet.ucla.edu)
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Antipsychoticeffectivenessmetabolicschizophrenia
Type
Commentaries
Information
Epidemiology and Psychiatric Sciences , Volume 22 , Issue 3 , September 2013 , pp. 239 - 240
Creative Commons
This is a work of the U.S. Government and is not subject to copyright protection in the United States.
Copyright
Copyright © Cambridge University Press 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Buchanan, RW, Kreyenbuhl, J, Kelly, DL, Noel, JM, Boggs, DL, Fischer, BA, Himelhoch, S, Fang, B, Peterson, E, Aquino, PR, Keller, W (2010). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin 36, 71–93.CrossRefGoogle ScholarPubMed
Garver, DL, Kelly, K, Fried, KA, Magnusson, M, Hirschowitz, J (1988). Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias). Psychological Medicine 18, 873–885.CrossRefGoogle ScholarPubMed
Jones, PB, Barnes, TR, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, Murray, RM, Markwick, A, Lewis, SW (2006). Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 63, 1079–1087.CrossRefGoogle Scholar
Kahn, RS, Fleischhacker, WW, Boter, H, Davidson, M, Vergouwe, Y, Keet, IP, Gheorghe, MD, Rybakowski, JK, Galderisi, S, Libiger, J, Hummer, M, Dollfus, S, Lopez-Ibor, JJ, Hranov, LG, Gaebel, W, Peuskens, J, Lindefors, N, Riecher-Rossler, A, Grobbee, DE (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371, 1085–1097.Google Scholar
Kinon, BJ, Chen, L, Ascher-Svanum, H, Stauffer, VL, Kollack-Walker, S, Zhou, W, Kapur, S, Kane, JM (2010). Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology 35, 581–590.CrossRefGoogle ScholarPubMed
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, Keefe, RS, Davis, SM, Davis, CE, Lebowitz, BD, Severe, J, Hsiao, JK (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209–1223.Google Scholar
Marder, SR, Essock, SM, Miller, AL, Buchanan, RW, Casey, DE, Davis, JM, Kane, JM, Lieberman, JA, Schooler, NR, Covell, N, Stroup, S, Weissman, EM, Wirshing, DA, Hall, CS, Pogach, L, Pi-Sunyer, X, Bigger, JT Jr, Friedman, A, Kleinberg, D, Yevich, SJ, Davis, B, Shon, S (2004). Physical health monitoring of patients with schizophrenia. American Journal of Psychiatry 161, 1334–1349.CrossRefGoogle ScholarPubMed
McEvoy, JP, Lieberman, JA, Perkins, DO, Hamer, RM, Gu, H, Lazarus, A, Sweitzer, D, Olexy, C, Weiden, P, Strakowski, SD (2007). Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. American Journal of Psychiatry 164, 1050–1060.CrossRefGoogle ScholarPubMed
Sikich, L, Frazier, JA, McClellan, J, Findling, RL, Vitiello, B, Ritz, L, Ambler, D, Puglia, M, Maloney, AE, Michael, E, De Jong, S, Slifka, K, Noyes, N, Hlastala, S, Pierson, L, McNamara, NK, Delporto-Bedoya, D, Anderson, R, Hamer, RM, Lieberman, JA (2008). Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. American Journal of Psychiatry 165, 1420–1431.Google Scholar